HR | 95% CI | P values | |
TCZ mono vs TNFi combo | 0.78 | 0.70 to 0.86 | <0.001 |
TNFi mono vs TNFi combo | 1.15 | 1.06 to 1.23 | <0.001 |
TCZ mono vs TCZ combo | 0.96 | 0.86 to 1.08 | 0.53 |
TCZ mono vs TNFi mono | 0.65 | 0.58 to 0.74 | <0.001 |
TCZ combo vs TNFi combo | 0.70 | 0.65 to 0.76 | <0.001 |
TCZ combo vs TNFi mono | 0.65 | 0.59 to 0.72 | <0.001 |
Adjusted by age, gender, disease duration, seropositivity, number of previous biologic disease-modifying antirheumatic drugs, glucocorticoids at baseline, Disease Activity Score 28 at baseline, Clinical Disease Activity Index at baseline, Health Assessment Questionnaire at baseline.
combo, combination therapy; mono, monotherapy; TCZ, tocilizumab; TNFi, tumour necrosis factor inhibitor.